Elisabeth Digifico

Via Manzoni 56
Rozzano, 20089, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB.

Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB.

Journal: Journal of translational medicine

Published: January 15, 2025

Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.

Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.

Journal: Frontiers in immunology

Published: December 05, 2022

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment.

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment.

Journal: Frontiers in oncology

Published: January 10, 2022

Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.

Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.

Journal: Journal for immunotherapy of cancer

Published: August 15, 2021

Macrophages and cancer stem cells: a malevolent alliance.

Macrophages and cancer stem cells: a malevolent alliance.

Journal: Molecular medicine (Cambridge, Mass.)

Published: June 16, 2021

Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy.

Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy.

Journal: European journal of immunology

Published: May 20, 2021

The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset.

The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset.

Journal: International journal of molecular sciences

Published: December 29, 2020

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing.

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing.

Journal: Journal of clinical medicine

Published: September 23, 2020

Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice.

Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice.

Journal: Cancers

Published: June 24, 2020

The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33.

The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33.

Journal: Cellular & molecular immunology

Published: December 16, 2019

Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages.

Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages.

Journal: European journal of immunology

Published: August 29, 2018

Targeting tumor associated macrophages: The new challenge for nanomedicine.

Targeting tumor associated macrophages: The new challenge for nanomedicine.

Journal: Seminars in immunology

Published: July 31, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026